MA43879B1 - Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones - Google Patents

Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Info

Publication number
MA43879B1
MA43879B1 MA43879A MA43879A MA43879B1 MA 43879 B1 MA43879 B1 MA 43879B1 MA 43879 A MA43879 A MA 43879A MA 43879 A MA43879 A MA 43879A MA 43879 B1 MA43879 B1 MA 43879B1
Authority
MA
Morocco
Prior art keywords
imipridones
modulation
protein
conditions
gpcr
Prior art date
Application number
MA43879A
Other languages
English (en)
French (fr)
Other versions
MA43879A (fr
Inventor
Martin Stogniew
Joshua E. Allen
Varun Vijay PRABHU
Original Assignee
Oncoceutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/en
Application filed by Oncoceutics, Inc. filed Critical Oncoceutics, Inc.
Publication of MA43879A publication Critical patent/MA43879A/fr
Publication of MA43879B1 publication Critical patent/MA43879B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
MA43879A 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones MA43879B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22
EP17745078.0A EP3408298B1 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones
PCT/US2017/015608 WO2017132661A2 (en) 2016-01-29 2017-01-30 G protein-coupled receptor (gpcr) modulation by imipridones

Publications (2)

Publication Number Publication Date
MA43879A MA43879A (fr) 2018-12-05
MA43879B1 true MA43879B1 (fr) 2025-02-28

Family

ID=59398848

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43879A MA43879B1 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Country Status (25)

Country Link
US (2) US11116771B2 (https=)
EP (2) EP4524567A3 (https=)
JP (3) JP7030701B2 (https=)
KR (2) KR102801670B1 (https=)
CN (2) CN115844895B (https=)
AU (2) AU2017211423B2 (https=)
BR (1) BR112018015590A2 (https=)
CA (2) CA3013044A1 (https=)
DK (1) DK3408298T3 (https=)
ES (1) ES3012491T3 (https=)
FI (1) FI3408298T3 (https=)
HR (1) HRP20250207T1 (https=)
HU (1) HUE070208T2 (https=)
IL (3) IL316540A (https=)
LT (1) LT3408298T (https=)
MA (1) MA43879B1 (https=)
MX (2) MX2018009227A (https=)
NZ (1) NZ745425A (https=)
PL (1) PL3408298T3 (https=)
PT (1) PT3408298T (https=)
RS (1) RS66519B1 (https=)
SG (2) SG11201806401YA (https=)
SI (1) SI3408298T1 (https=)
SM (1) SMT202500086T1 (https=)
WO (1) WO2017132661A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66519B1 (sr) * 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
EP3682035B1 (en) * 2017-09-15 2025-02-05 The Regents of the University of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
WO2019067709A1 (en) * 2017-09-27 2019-04-04 The Regents Of The University Of California GPCR IN FIBROBLASTS ASSOCIATED WITH CANCER
EP3745862B1 (en) 2018-01-31 2024-06-26 Mayo Foundation for Medical Education and Research D1 dopamine receptor agonists for treating fibrotic pathologies
EP3773520A4 (en) * 2018-04-09 2021-12-22 Orgenesis Inc. BIOXOMES AND REDOXOMES PARTICLES, PROCESS AND COMPOSITION
CN109157656B (zh) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 一种双靶标肿瘤疫苗及其制备方法和应用
US20220143024A1 (en) * 2019-02-22 2022-05-12 Board Of Regents, The University Of Texas System Methods of using imipridones
CA3148598A1 (en) 2019-07-30 2021-02-04 Mayo Foundation For Medical Education And Research Compounds and methods for treating fibrotic pathologies
KR102403686B1 (ko) 2020-05-15 2022-05-31 뉴로핏 주식회사 뇌자극 위치 제공장치 및 방법
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN112402439A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
JP2025525131A (ja) * 2022-08-03 2025-08-01 シ，シャンドン Ｄｒｄ１及び／又はｄｒｄ５に基づいて精神状態を決定する定量的方法、及びその適用
CN115531378B (zh) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Pht427作为ndm-1与kpc-2双重抑制剂的应用
WO2024157207A1 (en) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
EP4698146A1 (en) * 2023-04-20 2026-02-25 Institut Gustave-Roussy Liquid and solid compositions of imipridone derivatives
CN116731136B (zh) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20070026402A1 (en) * 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US8463365B2 (en) 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
EP3679934B1 (en) 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
SI2968294T1 (sl) 2013-03-13 2019-08-30 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
JP6756435B2 (ja) * 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
HUE052821T2 (hu) * 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
EP3408298B1 (en) 2024-11-20
ES3012491T3 (en) 2025-04-09
CN109311980B (zh) 2023-01-17
WO2017132661A3 (en) 2017-08-31
NZ784773A (en) 2025-05-02
SMT202500086T1 (it) 2025-03-12
US11116771B2 (en) 2021-09-14
SG10202108306UA (en) 2021-08-30
JP7825984B2 (ja) 2026-03-09
HUE070208T2 (hu) 2025-05-28
KR20180125460A (ko) 2018-11-23
NZ745425A (en) 2023-03-31
US20190307751A1 (en) 2019-10-10
LT3408298T (lt) 2025-03-10
CA3013044A1 (en) 2017-08-03
SG11201806401YA (en) 2018-08-30
AU2022200583A1 (en) 2022-02-24
JP2019511460A (ja) 2019-04-25
KR20250065717A (ko) 2025-05-13
CA3294566A1 (en) 2026-03-02
MX2023004443A (es) 2023-05-08
EP3408298A2 (en) 2018-12-05
BR112018015590A2 (pt) 2019-10-01
EP4524567A2 (en) 2025-03-19
KR102801670B1 (ko) 2025-04-25
IL286923B1 (en) 2024-12-01
WO2017132661A2 (en) 2017-08-03
CN115844895B (zh) 2025-10-17
PL3408298T3 (pl) 2025-03-31
DK3408298T3 (en) 2025-03-03
EP3408298A4 (en) 2019-09-04
AU2022200583B2 (en) 2024-05-02
AU2017211423A1 (en) 2018-09-06
SI3408298T1 (sl) 2025-05-30
HRP20250207T1 (hr) 2025-04-11
PT3408298T (pt) 2025-03-20
AU2017211423B2 (en) 2021-10-28
FI3408298T3 (fi) 2025-02-24
IL316540A (en) 2024-12-01
EP4524567A3 (en) 2025-07-23
MX2018009227A (es) 2018-11-09
JP2022046528A (ja) 2022-03-23
MA43879A (fr) 2018-12-05
IL286923B2 (en) 2025-04-01
CN109311980A (zh) 2019-02-05
US20220072001A1 (en) 2022-03-10
IL286923A (en) 2021-10-31
IL260815B (en) 2021-10-31
JP7030701B2 (ja) 2022-03-07
JP2026016502A (ja) 2026-02-03
RS66519B1 (sr) 2025-03-31
CN115844895A (zh) 2023-03-28

Similar Documents

Publication Publication Date Title
MA43879B1 (fr) Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
MA34458B1 (fr) Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1
EP3607715A4 (en) DETECTING A CONSUMER RESTART OF A NF SERVICE USING DIRECT SIGNALING BETWEEN NFS
MA49459A (fr) Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
FR3030516B1 (fr) Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
MA43468A1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA33571B1 (fr) Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline
MA46148A1 (fr) Systèmes et procédés de capture d'image dans une capsule de culture de ligne d'assemblage
CO6210723A2 (es) Combinaciones de benzotiazolona agonista de receptores adrenergicos beta 2
EA201000319A1 (ru) Производные азациклилизохинолинона и изоиндолинона в качестве антагонистов гистаминовых рецепторов подтипа 3
WO2018220060A3 (en) INSTRUMENT FITTINGS AND ASSOCIATED METHODS
MX2019013734A (es) Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis.
HUE068662T2 (hu) Angiotenzin-ii-receptor-2 agonista új alkalmazása
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
NZ764026A (en) Imipridones for gliomas
MA41730A1 (fr) Utilisation de dérivé de benzimidazole pour l'acidité nocturne
EP3766207A4 (en) DEVICES AND METHODS FOR QOS DETERMINATION OF IOT-BASED APPLICATIONS
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
AR058959A1 (es) Metodos para modular receptores de la superficie celular para prevenir o reducir la inmflamacion
FR3028317B1 (fr) Systeme pour l'evaluation d'au moins un analyte susceptible d'etre contenu dans un echantillon liquide depose sur un dispositif immunochromatographique
FR3019654B1 (fr) Controles pour la mise en oeuvre de procedes d'analyse multiplexe
EP1741792A4 (en) NEW LIGAND OF A G-PROTEIN-CONJUGATED RECEPTOR PROTEIN AND USE THEREOF
FR3048883B1 (fr) Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique